Ultragenyx shares tumble lower after rare disease drug fails PhII trial
Shares of Ultragenyx $RARE tumbled close to 10% after the rare disease biotech reported that one of its drugs failed a Phase II trial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
